Cystic Fibrosis Therapeutics Market Size is projected to reach USD 13.88 billion in 2030, growing at a CAGR of 9.12%: Straits Research
March 14, 2023 08:30 ET
|
Straits Research
New York, United States, March 14, 2023 (GLOBE NEWSWIRE) -- Cystic fibrosis is a genetic condition that mostly impacts the lungs but can also impact other organs and systems in the body such as the...
First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis
March 10, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 10, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
March 09, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 09, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Respiratory Inhalers Market Share ($43.44 Billion by 2028) Driven by Rising Prevalence of Asthma – Global Report by The Insight Partners
March 06, 2023 06:38 ET
|
The Insight Partners
New York, March 06, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Respiratory Inhalers Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global...
First Wave BioPharma to Participate in ‘Fireside Chat’ at the 35th Annual Roth Conference
February 28, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference
February 21, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
February 13, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis
February 02, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
January 31, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma to Present at the BIO CEO & Investor Conference
January 30, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...